194 related articles for article (PubMed ID: 16281428)
1. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
Berry DA
Clin Trials; 2005; 2(4):295-300; discussion 301-4, 364-78. PubMed ID: 16281428
[TBL] [Abstract][Full Text] [Related]
2. A case for Bayesianism in clinical trials.
Berry DA
Stat Med; 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PubMed ID: 8248653
[TBL] [Abstract][Full Text] [Related]
3. Bayesian clinical trials.
Berry DA
Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
[TBL] [Abstract][Full Text] [Related]
4. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
7. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
8. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
Zaslavsky BG
Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
[TBL] [Abstract][Full Text] [Related]
9. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
van Noord PA; van der Tweel I
Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
[No Abstract] [Full Text] [Related]
10. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
Adrion C; Mansmann U
BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
[TBL] [Abstract][Full Text] [Related]
11. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.
Kpozèhouen A; Alioum A; Anglaret X; Van de Perre P; Chêne G; Salamon R
Am J Epidemiol; 2005 Mar; 161(6):595-603. PubMed ID: 15746476
[TBL] [Abstract][Full Text] [Related]
12. Bayesian randomized clinical trials: From fixed to adaptive design.
Yin G; Lam CK; Shi H
Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
[TBL] [Abstract][Full Text] [Related]
13. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
14. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
15. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
16. Adaptive Bayesian randomized trials: realizing their potential.
Pullenayegum EM
J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
18. Optimal sample size determinations from an industry perspective based on the expected value of information.
Willan AR
Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
[TBL] [Abstract][Full Text] [Related]
19. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
20. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
